logo
welcome
ScienceDaily

ScienceDaily

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF-mutated metastatic colorectal cancer

ScienceDaily
Summary
Nutrition label

82% Informative

Combination of dual-targeted therapies and chemotherapy shows high response rates in BRAF -mutated metastatic colorectal cancer Phase III trial results supported recent FDA approval for patients with BRAF V600E mutations.

The findings were presented today at the American Society of Clinical Oncology Gastrointestinal Cancers (ASCO GI ) Annual Symposium.

Story Source: Journal Reference: - Kopetz, S. , Yoshino , T. , Van Cutsem , E. et al . Encorafenib, cetuximab and chemotherapy in BRAF-mutant colorectal cancer: a randomized phase 3 trial. Nat Med , 2025 DOI: 10.1038 /s41591-024-03443-3 Cite This Page:.

VR Score

91

Informative language

98

Neutral language

65

Article tone

formal

Language

English

Language complexity

78

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

long-living

External references

no external sources

Source diversity

no sources

Affiliate links

no affiliate links